Scarica l'app Stockscreener
45.46
2.57%
-1.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$46.66
Aprire:
$46.47
Volume 24 ore:
415.08K
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.55B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
42.50
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
-1.17%
1M Prestazione:
+10.23%
6M Prestazione:
+44.87%
1 anno Prestazione:
+47.12%
Intervallo 1D:
$45.39
$46.67
Intervallo di 1 settimana:
$45.26
$46.78
Portata 52W:
$29.16
$46.78
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
45.46 | 2.59B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - MSN
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - Yahoo Finance
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceut - PharmiWeb.com
Published on: 2025-09-08 10:08:24 - beatles.ru
Will Supernus Pharmaceuticals Inc. benefit from rising consumer demandPortfolio Return Summary & High Conviction Buy Zone Picks - خودرو بانک
Stock Analysis: Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Outlook & Daily Chart Pattern Signal Reports - خودرو بانک
How to use a screener to detect Supernus Pharmaceuticals Inc. breakouts2025 Sector Review & AI Based Buy/Sell Signal Reports - Newser
Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesEarnings Recap Summary & Precise Buy Zone Tips - خودرو بانک
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Can Supernus Pharmaceuticals Inc. expand into new markets2025 Price Targets & Free Community Supported Trade Ideas - خودرو بانک
Analyzing recovery setups for Supernus Pharmaceuticals Inc. investorsMarket Trend Review & Daily Stock Momentum Reports - Newser
Will Supernus Pharmaceuticals Inc. benefit from sector rotationJuly 2025 Gainers & AI Driven Stock Movement Reports - خودرو بانک
Analyzing net buyer seller activity in Supernus Pharmaceuticals Inc.July 2025 Sentiment & Weekly Breakout Stock Alerts - Newser
What’s the beta of Supernus Pharmaceuticals Inc. stockMarket Trend Report & Weekly Return Optimization Alerts - خودرو بانک
Has Supernus Pharmaceuticals Inc. found a price floorWeekly Profit Summary & Daily Chart Pattern Signals - Newser
How high can Supernus Pharmaceuticals Inc. stock goJuly 2025 PreEarnings & Real-Time Price Movement Reports - Newser
Supernus at Wells Fargo Conference: Strategic Growth in CNS By Investing.com - Investing.com Canada
Will Supernus Pharmaceuticals Inc. benefit from geopolitical trends2025 Investor Takeaways & Low Risk Growth Stock Ideas - خودرو بانک
Published on: 2025-09-04 06:09:28 - Newser
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Predicting Supernus Pharmaceuticals Inc. trend using moving averagesMarket Risk Analysis & Long-Term Safe Investment Ideas - Newser
How sentiment analysis helps forecast Supernus Pharmaceuticals Inc.July 2025 Setups & High Yield Equity Trading Tips - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Will earnings trigger a reversal in Supernus Pharmaceuticals Inc.July 2025 Summary & Safe Capital Preservation Plans - Newser
Will Supernus Pharmaceuticals Inc. benefit from seasonalityMarket Sentiment Review & Reliable Entry Point Alerts - خودرو بانک
Real time breakdown of Supernus Pharmaceuticals Inc. stock performanceNew Guidance & Intraday High Probability Alerts - Newser
Supernus Pharmaceuticals stock hits 52-week high at $45.85 By Investing.com - Investing.com Canada
Risk vs reward if holding onto Supernus Pharmaceuticals Inc.July 2025 Pullbacks & High Conviction Buy Zone Alerts - Newser
Custom strategy builders for tracking Supernus Pharmaceuticals Inc.July 2025 Final Week & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Supernus Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Sector ETF performance correlation with Supernus Pharmaceuticals Inc.2025 Price Action Summary & AI Driven Price Predictions - Newser
Candlestick signals on Supernus Pharmaceuticals Inc. stock today2025 Technical Patterns & Real-Time Buy Signal Notifications - Newser
Will Supernus Pharmaceuticals Inc. stock recover after earnings2025 Market Overview & Low Risk Profit Maximizing Plans - خودرو بانک
Supernus Pharmaceuticals stock hits 52-week high at $45.85 - Investing.com
EV Market: What are Supernus Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Return Report & Detailed Earnings Play Strategies - خودرو بانک
Using data filters to optimize entry into Supernus Pharmaceuticals Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
What hedge funds are buying Supernus Pharmaceuticals Inc.July 2025 Decliners & AI Driven Price Forecasts - خودرو بانک
Is Supernus Pharmaceuticals Inc. stock showing strong momentum2025 Biggest Moves & Daily Profit Maximizing Tips - خودرو بانک
What technical models suggest about Supernus Pharmaceuticals Inc.’s comebackPrice Action & Reliable Entry Point Trade Alerts - Newser
Market Outlook: What is the long term forecast for Supernus Pharmaceuticals Inc. stockBear Alert & Safe Entry Momentum Stock Tips - خودرو بانک
What are Supernus Pharmaceuticals Inc.’s earnings expectationsWeekly Risk Report & Stepwise Trade Execution Plans - خودرو بانک
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Sep 08 '25 |
Option Exercise |
25.30 |
8,074 |
204,272 |
1,118,305 |
| Khattar Jack A. | President, CEO |
Sep 08 '25 |
Sale |
46.29 |
6,322 |
292,645 |
1,111,983 |
| Khattar Jack A. | President, CEO |
Sep 05 '25 |
Option Exercise |
25.30 |
73,176 |
1,851,353 |
1,165,809 |
| Khattar Jack A. | President, CEO |
Sep 05 '25 |
Sale |
46.01 |
55,578 |
2,557,144 |
1,110,231 |
2.67%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):